Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 1b clinical study titled ‘A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis.’ The study aims to evaluate the safety and tolerability of ABBV-744, alone and in combination with ruxolitinib or navitoclax, in adults with myelofibrosis, a serious bone marrow disorder. This research is significant as it explores new treatment options for a condition with limited therapies.
The study tests ABBV-744, an investigational drug, both as a standalone treatment and in combination with ruxolitinib and navitoclax. These drugs are administered orally and are intended to manage myelofibrosis symptoms and progression.
This interventional study is non-randomized and follows a sequential intervention model without masking, focusing primarily on treatment. It is designed to identify safe dosing regimens and assess the effectiveness of combination therapies.
The study began on November 11, 2020, with an estimated primary completion date in 2025. The last update was submitted on July 14, 2025, indicating ongoing progress and adjustments.
This study update could influence AbbVie’s stock performance positively, as successful results may enhance their portfolio in the myelofibrosis treatment market. Investors should watch for competitor developments in this niche sector.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.